NICE rebuffs Avastin for colorectal cancer

The U.K.'s NICE issued a second preliminary appraisal recommending against the use of Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY)

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE